Keryx Biopharmaceuticals Inc. $ 0.60
Short Interest (Shares Short) 10,333,100
Days To Cover (Short Interest Ratio) 1.2
Short Percent of Float 24.82 %
Short Interest - Prior 14,370,000
Short % Increase / Decrease -28.09 %
Short Squeeze Ranking™ -28
Short Interest sinkt,nur noch noch 1,2 Tage zum Covern.
Das dürfte uns spätestens im April in das Gap führen:
Keryx inks $100M deal with Japan Tobacco
September 26, 2007
Tags experimental therapy Phase II
Japan Tobacco and its subsidiary Torii Pharmaceutical will pay up to $100 million for the Japanese licensing rights to Keryx's experimental therapy for high phosphorous levels in the blood. Up to $20 million of that money will become available by April, 2008. The drug, Zerenex, is in Phase II clinical trials in the U.S.
"They have proven themselves to be ideal partners for smaller U.S.-based biotechnology companies seeking development and commercial partners in Japan," said Michael S. Weiss, chairman and CEO of Keryx, about his new partners.
Next week could be a nice week.
Schön wäre ne PR in Bezug auf die 20 Millionen $.